ProCE Banner Activity

CME

New Treatment Strategies in Aggressive B-Cell Lymphomas: Advances, Application, and a Glimpse of the Future

Multimedia
In this on-demand webcast from a live symposium, oncology Julie M. Vose, MD, MBA; Jeremy S. Abramson, MD, MMSc; and Grzegorz S. Nowakowski, MD discuss the recent and evolving treatment strategies in the management of patients with aggressive B-cell lymphomas.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 08, 2022

Expiration: June 07, 2023

No longer available for credit.

Share

Faculty

Julie M. Vose

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Jeremy S. Abramson

Jeremy S. Abramson, MD, MMSc

Director, Hagler Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Grzegorz Nowakowski

Grzegorz Nowakowski, MD

Professor of Medicine and Oncology
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Genmab US

Incyte Corporation

Lilly

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who treat patients with B cell lymphomas.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Order and interpret molecular profiling for appropriate patients with MCL and DLBCL to guide therapy selection
  • Select treatment regimens for patients with MCL and DLBCL based on available clinical data, disease characteristics, and individual patient goals and preferences to optimize clinical outcomes
  • Identify patients with aggressive B-cell lymphoma who would likely benefit from enrollment on a clinical trial
  • Mitigate, monitor, and manage adverse events associated with newer therapeutic regimens used in the treatment of MCL and DLBCL

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Daiichi Sankyo, Genentech, Janssen, Lilly, and MEI Pharma.

Faculty Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc

Director, Hagler Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Jeremy S. Abramson, MD, MMSc, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, BeiGene, Bluebird, Bristol-Myers Squibb, Century, Epizyme, Genentech, Genmab, Incyte, Kite, Kymera, Lilly, MorphoSys, Mustang, Ono, and Regeneron.

Grzegorz Nowakowski, MD

Professor of Medicine and Oncology
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Grzegorz S. Nowakowski, MD, has disclosed that he has received consulting fees from AbbVie, ADC Therapeutics, Bantam Pharmaceutical LLC, Blueprint Medicines, Bristol-Myers Squibb, Celgene Corporation, Curis, Debiopharm, F Hoffmann-La Roche Limited, Fate Therapeutics, Genentech, Incyte, Karyopharm Therapeutics, Kite Pharma, Kymera Therapeutics, MEI Pharma, MorphoSys AG, Ryvu Therapeutics, Seagen, Selvita Inc, TG Therapeutics, and Zai Lab Limited.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kemi Obajimi, PhD

Scientific Director

Kemi Obajimi, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 08, 2022, through June 07, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of learners in selecting individualized treatments for patients with MCL and DLBCL.